Mirum Pharmaceuticals, Inc. (MIRM) Tops Q2 EPS by 21c

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q2 EPS of ($0.12), $0.21 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $127.78 million versus the consensus estimate of $107.36 million.

For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.

You May Also Be Interested In

• SolarEdge (SEDG) PT Lowered to $31 at Jefferies, 'We see shares as an unappealing short, not a compelling long'
• HealthEquity (HQY) Tops Q2 EPS by 5c ; Offers Guidance
• TETRA Technologies (TTI) call put ratio 2 calls to 1 put with a focus on September 7 calls and March 7 puts